Tempest Therapeutics, Inc. announced new and updated positive results from the planned data analysis of an ongoing global randomized Phase 1b/2 clinical study in which TPST-1120, Tempest's PPAR antagonist, shows clinical superiority in multiple study endpoints when combined with atezolizumab and bevacizumab in a randomized comparison to atezolizumab & bevacizumabin in the first-line treatment of patients with unresectable or metastatic hepatocellular carcinoma ("HCC"). The Phase 1b/2 global randomized HCC study is part of Roche's Morpheus program and evaluates TPST-1120 in combination with atezolizumib and bevacizumib, the standard of care, in patients with unresectable and metastatic HCC not previously treated with systemic therapy. In a Phase 1 clinical trial in patients with heavily-pretreated advanced solid tumors, TPST-1120 as monotherapy and in combination with thePD-1 inhibitor nivolumab demonstrated tumor reduction (including according to RECIST criteria), as well as biomarker modulation.

All statements that are not historical facts are forward-looking statements, including any statements regarding the availability of data from clinical trials, the ability of the company or its collaborators to present such data at certain conferences, and the ability of the company to advance discussions with potential partners to explore the development of TPST-1120.